Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Weightmasters reveal successful results from clinical trials on Natural Appetite Suppressant, Opriimo
  • USA - English


News provided by

Your Lifestyle Products Ltd

Jan 28, 2014, 06:35 ET

Share this article

Share toX

Share this article

Share toX

Natural Appetite Suppressant for Weight Management and the supportive treatment of excess weight
Natural Appetite Suppressant for Weight Management and the supportive treatment of excess weight

(PRWEB UK) 28 January 2014 -- The recent BBC report on January 3rd revealed shocking figures of obesity quadrupling to nearly one billion in the developing world since the 1980s. 64% of adults are now classified as overweight or obese in the UK. With high levels of cheap convenience food available, and the increasing numbers of overweight Brits on the increase, Weightmasters have revealed successful results from clinical trials on their Natural Appetite Suppressant, Opriimo. (http://www.bbc.co.uk/news/health-25576400)

"Weightmasters have revealed successful results from clinical trials on their Natural Appetite Suppressant, Opriimo."

Post this

Opriimo is a revolutionary NEW weight management solution. It’s a medical device and Natural Appetite Suppressant proven for weight management and the supportive treatment of excess weight. Unlike its closest comparable forms of Gastric Surgery, it’s totally non-invasive, and available without hospital stay or prescription.

The effectiveness and tolerability of Opriimo has been investigated through three different clinical trials. All three were placebo-controlled, randomised, double-blind crossover studies. The clinical studies involved subjects, undergoing a series of methods over a 12-week period. The premise of these studies was to establish the ingredient, Alginate’s effects towards weight reduction, satiation (appetite suppression) and the regulation of appetite.

Summarised results of Clinical Trials:

Alginate (a natural sponge, similar to seaweed), expands in the stomach. Radiological tests have demonstrated that the alginate solids remain in the stomach for up to 8 hours. (Krakamp et al 2000).

The sponges meet with the stomach wall and stimulate the receptors, which transmit a feeling of satiation (fullness), usually within 20 –30 minutes of eating. (Schusdziarra 1996).

Where the capsules were taken 20– 30 minutes before meals, excellent or favourable pre-satiation (fullness before eating) was achieved in 85 % of all participants during studies. (Willmen et al 1999).

Clinical Trial 1: The Investigation into the satiation effect of Alginate bodies. (Willmen 2002)
Undertaken to determine the satiation effect of Alginate bodies, 46 subjects were assessed where randomly selected subjects were given the Alginate (active group), while others given a placebo. The Results were significant in favour of the active group given Alginate. No clinically relevant side effects were observed.

Clinical Trial 2: The Investigation into significant weight reduction by stimulation of satiation sensors. (Willmen 2002)
Undertaken to determine the effectiveness of Alginate for weight loss and Satiation. 139 subjects took part in this investigation over 12 weeks. They took 3 x 3 capsules before main meals. Subjects given Alginate (active group) showed a more significant weight reduction (of up to 9.4Kg) compared to those taking the placebo. Additionally, satiation scores were significantly higher and less subjects dropped out of the trial from the active group.

Clinical Trial 3: Investigation into the regulation of appetite. (Willmen 2002)
Undertaken to determine the effectiveness of Alginate for the regulation of appetite. 25 subjects took part in this investigation. This was a mixed male / female group, aged between 18-70, all were normal weight. Randomly some subjects were given the Alginate capsules 3 x 3 per day (the active group), while others given a placebo. Subject groups were assessed regarding the calories consumed and saved. Results were statistically significant in favour of the active group. The calculation of the amount of food into calories showed that the participants consumed an average reduction of 158 less calories per day. Calculated on a yearly basis this calorie reduction equates to 57670 Kcal with a weight loss of 8Kg.

Additionally the reduction of appetite was 82.5 % in the active group, plus significantly less food was consumed and the appetite was lower. The differences between the groups were significant in favour of those taking Alginate (active group). No clinically relevant side effects were observed.

---

From the results of the three different clinical trials, the product has been proven as an effective Natural Appetite Suppressant for weight management and the supportive treatment of excess weight. It has been awarded CE product certification and approval from MHRA under EU Medical Device directives.

The results of the clinical trials have been summarised for ease of reading. The full clinical reports from the trials are available on request from csuk(at)opriimo(dot)com.

About Opriimo:
Opriimo is a revolutionary new medical device designed to help people eat less, feel full and manage weight. It’s totally non-invasive, so no surgery is required. There are no complicated diets to follow, and it is clinically proven.
Opriimo also comes with full 1:1 support from a personal weight management consultant.
•     Certified Medical Device
•     Clinically Proven
•     Non Invasive (No Surgery Required)
•     No Complicated Diets to follow
•     Includes 1:1 support from your own personal weight management consultant.

Because of the nature of the product, Opriimo is not suitable for all, and some qualification criteria apply.

For more details, contact Weightmasters on 0208 619 0025 or email csuk(at)opriimo(dot)com.

Michael Kitt, Your Lifestyle Products Ltd, http://www.yourlifestyle.com, +44 2085889144, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.